Loading clinical trials...
Loading clinical trials...
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
NCT03734198 · Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT04872621 · Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
NCT03206918 · Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
NCT01578707 · Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Investigational Site
Baltimore, Maryland
Investigational Site
Charlotte, North Carolina
Investigational Site
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions